ABSTRACT
Growth Hormone being very expensive in India data on use of recombinant human growth hormone (rhGH) is scarce. The authors studied the effect and safety of one year of therapy with rhGH on growth velocity and predicted final height in Indian patients with growth hormone deficiency (GHD). A multicentric, prospective, open trial with rhGH was performed on 15 patients. Patients received rhGH in a dose of 0.7 IU (0.23 mg)/Kg/week. The mean pretreatment height was 111.2 cms {SD 12.4}, height velocity was 3.1 cms per year {1.2} and predicted height was 146.5 cms {10.4} at a mean age of 12.0 (2.8). At the end of therapy mean height was 123.4 {11.9}, height velocity was 12.1 cms per year {2.8} and the predicted height was 153.0 cm {9.4}. The increase in predicted height was thus 6.5 cm (4.2). The increment in height velocity with growth hormone therapy was statistically significant (p value= 0.001). The present study shows that children with growth hormone deficiency in India also benefit from therapy with rhGH even when treatment is started late as compared to the published Western data and there is a potential for increased final height.
Subject(s)
Adolescent , Age Factors , Body Height/drug effects , Child , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug-Related Side Effects and Adverse Reactions , Female , Follow-Up Studies , Growth Disorders/drug therapy , Human Growth Hormone/deficiency , Humans , India , Injections, Subcutaneous , Male , Prospective Studies , Risk Factors , Severity of Illness Index , Sex Factors , Treatment OutcomeABSTRACT
The aim of our study was to determine the pattern of female reproductive organ growth in Indian girls from birth to 18 years of age and to correlate the uterine length, mean ovarian volume (MOV) and Fundo Cervical Ratio (FCR) with chronological age, bone age and pubertal breast staging. A cross sectional study was performed on 218 girls from birth to 18 years of age. Height, weight, stage of puberty, X-ray for bone age and transabdominal ultrasounds were performed on all girls. Higher chronological age, bone age and increase in breast stage significantly predicted higher MOV (P < 0.001) and higher uterine length (P < 0.001). The MOV, uterine length and FCR are positively correlated with chronological age, bone age, height, weight and breast staging. Data from present study may be useful in screening cases of precocious puberty and other disorders that may need further evaluation.
Subject(s)
Adolescent , Adolescent Development/physiology , Age Factors , Breast/growth & development , Child , Child Development/physiology , Child, Preschool , Cross-Sectional Studies , Female , Humans , India , Infant , Infant, Newborn , Menarche/physiology , Ovary/growth & development , Uterus/growth & developmentABSTRACT
We assessed the effect of one year of therapy with recombinant Human Growth Hormone (rhGH) on growth velocity of 16 Indian girls with Turner Syndrome (TS) in a prospective, open trial. Patients received rhGH in a dose of 1 IU (0.3 mg)/kg/week. The mean pretreatment height was 117.1 cms (Z score minus 3.4), height velocity was 3.8 cm per year (Z score minus 2.4), and predicted height was 140 cm. At the end of therapy mean height was 123.9 (Z score minus 3.1), height velocity was 6.7 cm per year (Z score + 1.7), and the predicted height was 142.4 cm. The increment in height velocity with growth hormone therapy was statistically significant (P value = 0.001) and the mean increment in predicted height was 2.4 cm. Our study shows that girls with TS in India benefit from therapy with rhGH.
Subject(s)
Adolescent , Child , Female , Growth/drug effects , Human Growth Hormone/therapeutic use , Humans , Prospective Studies , Recombinant Proteins , Turner Syndrome/drug therapyABSTRACT
OBJECTIVES: 1. To compare growth parameters of patients with Congenital Adrenal Hyperplasia (CAH) managed on Prednisolone (PR) before and on Hydrocortisone (HC) after its availability in India. 2. To compare growth parameters of patients with CAH who have been on treatment with HC since diagnosis with patients managed on PR. METHODS: Growth parameters of twelve children (8 m, 4 f) with congenital adrenal hyperplasia were retrospectively studied while on treatment with prednisolone (PR) earlier and then hydrocortisone (HC) after it became freely available in India. RESULTS: Patients treated with PR had height Z score of -0.42, weight Z score of - 0.45, and height velocity Z score of -2.06. On HC these scores were -0.27, +0.16 and + 2.27. Patients treated with HC from the begining had a height Z Score of + 0.08, weight Z score of +0.22, and height velocity Z score of +0.68. CONCLUSION: Hydrocortisone has a less growth effect than prednisolone and patients treated with HC from the beginning showed near normal growth.
Subject(s)
Administration, Oral , Adrenal Hyperplasia, Congenital/drug therapy , Anti-Inflammatory Agents/administration & dosage , Child , Child, Preschool , Data Interpretation, Statistical , Female , Fludrocortisone/administration & dosage , Growth/drug effects , Humans , Hydrocortisone/administration & dosage , India , Infant , Infant, Newborn , Male , Prednisolone/administration & dosage , Retrospective StudiesABSTRACT
Growth hormone when used in precocious puberty in combination with Gonadotropin releasing hormone analogue (GnRHa) instead of using GnRHa alone has been shown to improve final height prognosis. We report here a two-year follow-up of three cases of precocious puberty, two of whom were treated with a combination of GH and GnRHa and the third treated with GnRHa alone.
Subject(s)
Body Height , Child , Child, Preschool , Drug Therapy, Combination , Female , Gonadotropin-Releasing Hormone/therapeutic use , Growth Hormone/therapeutic use , Humans , Puberty, Precocious/drug therapyABSTRACT
The bisphosphonates inhibit osteoclastic bone resorption and have been used as an intravenous infusion in fibrous dysplasia of the bone. Oral bisphosphonates are cheaper and also easy to administer. We report a case of polyostotic fibrous dysplasia in a three-year-old child who showed significant improvement in bone mineral density after treatment with oral alendronate.